Citi Credit Research Sees Opportunity in Valeant (VRX), Initiates With Overweight Rating (MNK) (ENDP)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Left for Dead Valeant Pharma (VRX) Is Up 30% In a Week
November 23, 2015 10:43 AM ESTShort seller target Valeant Pharma (NYSE: VRX) is continuing to rally sharply off oversold conditions following a few modest positives over the past week or so:
Citi launched coverage on the... MoreGuggenheim Remains Positive on Mallinckrodt (MNK) Post 4Q Beat
November 23, 2015 10:37 AM ESTGuggenheim maintained a Buy rating and $130.00 price target on Mallinckrodt plc (NYSE: MNK) following the company's 4Q earnings report. MNK reported F4Q15 EPS of $1.84, $0.09 higher than consensus. Management reaffirmed its F'16 EPS guidance of $7.70 to $8.20 compared to consensus of $7.91.
Analyst Louise... More
Valeant Pharma (VRX) Adds to Strong Gains; Sets Sights on $90
November 20, 2015 1:10 PM ESTShort seller target Valeant Pharma (NYSE: VRX) is seeing notably strength again today on the back of yesterday's 16% move up. Shares last traded up 5.6% to $88.73.
Yesterday, Citi endorsed the credit with an Overweight rating and today Mizuho reiterated it as a top pick, saying "the stock appears to have bottomed."
... MoreValeant Pharma (VRX) to Host December 16 Investor Day
November 20, 2015 9:00 AM ESTShort seller target Valeant Pharma (NYSE: VRX) announced it will will be hosting an Investor Day on December 16, 2015 where the Company will be providing updated financial guidance, discussing certain business operations and highlighting certain R&D programs.
Conference Call and Webcast... More
Valeant Pharmaceuticals (VRX) Reiterated Top Pick at Mizuho Securities; PT to $111
November 20, 2015 6:36 AM ESTMizuho Securities analyst Irina Koffler reiterated Valeant Pharmaceuticals (NYSE: VRX) as their Top Pick while maintaining an Outperform rating and lowering thier price target to $111.00 (from $155.00).
The analyst highlighted:
The stock appears to have bottomed, in our view: We are by no means ignoring the risks tied to this stock. We worry about expansion of existing investigations, congressional probes of Philidor, and potential changes to senior management. All that said, we believe that the risk/reward in VRX is still favorable given business fundamentals. We are primarily... MoreValeant Pharma (VRX) Surges as Co's Debt Gets Endorsed
November 19, 2015 10:05 AM ESTBeaten down Valeant Pharma (NYSE: VRX) is up 9% early to $79, benefiting from today's Overweight rating on the company's debt at Citi.
The firm cited product diversification and strong FCF generation.
... More